# Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

> **NCT00576914** · PHASE3 · UNKNOWN · sponsor: **Chinese Academy of Sciences** · enrollment: 1108 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** recombinant human endostatin

## Key facts

- **NCT ID:** NCT00576914
- **Lead sponsor:** Chinese Academy of Sciences
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-06
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 1108 (ESTIMATED)
- **Last updated:** 2010-03-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00576914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00576914, "Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00576914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*